Genc, S. Et Al. 2024. Evolving Clinical Features of Diabetic Ketoacidosis: The Impact of SGLT2 Inhibitors. Pharmaceuticals , vol.17, no.11 .

Genc, S., EVREN, B., Yigit, O. S., Sahin, I., Dayanan, R., Klisic, A., ... ERTÜRK, A.(2024). Evolving Clinical Features of Diabetic Ketoacidosis: The Impact of SGLT2 Inhibitors. Pharmaceuticals , vol.17, no.11.

Genc, Selin Et Al. "Evolving Clinical Features of Diabetic Ketoacidosis: The Impact of SGLT2 Inhibitors," Pharmaceuticals , vol.17, no.11, 2024

Genc, Selin Et Al. "Evolving Clinical Features of Diabetic Ketoacidosis: The Impact of SGLT2 Inhibitors." Pharmaceuticals , vol.17, no.11, 2024

Genc, S. Et Al. (2024) . "Evolving Clinical Features of Diabetic Ketoacidosis: The Impact of SGLT2 Inhibitors." Pharmaceuticals , vol.17, no.11.

@article{article, author={Selin Genc Et Al. }, title={Evolving Clinical Features of Diabetic Ketoacidosis: The Impact of SGLT2 Inhibitors}, journal={Pharmaceuticals}, year=2024}